IPO market

Unlisted Ideas

Invest in Pre-IPO shares

IPO Ideas

Invest in IPO in just 3 clicks

About Us

Symbiotec Pharmalab IPO subscription

BBMainboardBSE, NSE

Latest GMPGMP Updated 16 hr ago

333 Seller

+33.70%

Symbiotec Pharmalab IPO is a Mainboard IPO. Issue size is ₹1,757 Cr. Price band is ₹938 to ₹988 per share. Minimum investment is ₹14,820. Lot size is 15 shares. Open from 24 Aug 2026 to 27 Aug 2026. on 28 Aug 2026. Listing on 1 Sept 2026 at BSE, NSE. Managed by JM Financial Ltd., Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd., and Nomura Financial Advisory & Securities (India) Pvt.Ltd. Registrar: MUFG Intime India Private Limited (Link Intime). Key details for GMP, subscription, price, , and listing in one place.

Live IPO subscription for Symbiotec Pharmalab IPO across categories. Total demand ₹7.00 Cr vs offered ₹1.25 Cr.

Official documents:DRHP.

Follow the latest IPO & unlisted research on iOS and Android.

Google Play App Store

Symbiotec Pharmalab IPO subscription

BBMainboardBSE, NSE

Latest GMPGMP Updated 16 hr ago

333 Seller

+33.70%

Live IPO subscription for Symbiotec Pharmalab IPO across categories. Total demand ₹7.00 Cr vs offered ₹1.25 Cr.

Official documents:DRHP.

Subscription Status

Category	Offered	Placed	Times
QII	35,50,608	22,13,355	0.62
NII	26,62,955	3,42,54,810	12.86
NII (>10L)	17,75,303	2,11,24,395	11.90
NII (<10L)	8,87,652	1,31,30,415	14.79
Retail	62,13,562	3,33,49,875	5.37
Employee	33,408	2,09,115	6.26
Total	1,24,60,533	7,00,27,155	5.62

Application Wise Subscription

Category	Offered	Placed	Times
HNI (>10L)	8,453	20,345	2.41
HNI (3-10L)	4,226	60,085	14.22
Retail	414,237	1,917,952	4.63
Employee	-	9,012	-
Total	426,916	2,007,394	4.70

Symbiotec Pharmalab IPO subscription FAQs

How to read QIB / NII / Retail demand and what it implies.

What is the Symbiotec Pharmalab IPO subscription status?

The Symbiotec Pharmalab IPO subscription status shows how many times the issue has been subscribed across different investor categories such as QIB, NII (HNI), and Retail. It reflects the demand for the IPO during the subscription period.

Where can I check live Symbiotec Pharmalab IPO subscription numbers?

You can check live Symbiotec Pharmalab IPO subscription data on this page, which is updated based on official data released during the IPO subscription period.

What are the investor categories in Symbiotec Pharmalab IPO subscription?

The Symbiotec Pharmalab IPO subscription is divided into the following categories: Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII / HNI), and Retail Individual Investors (RII). Each category has a separate quota and subscription data.

What does QIB subscription mean in Symbiotec Pharmalab IPO?

QIB subscription in Symbiotec Pharmalab IPO indicates the demand from institutional investors such as mutual funds, banks, and insurance companies.

What does NII or HNI subscription mean in Symbiotec Pharmalab IPO?

NII (also known as HNI) subscription in Symbiotec Pharmalab IPO represents bids from high-net-worth investors who apply for shares above the retail limit.

What does Retail subscription mean in Symbiotec Pharmalab IPO?

Retail subscription in Symbiotec Pharmalab IPO shows demand from individual investors who apply within the retail investment limit specified in the IPO details.

How often is Symbiotec Pharmalab IPO subscription data updated?

Symbiotec Pharmalab IPO subscription data is updated multiple times during market hours based on information published by stock exchanges.

Does higher Symbiotec Pharmalab IPO subscription guarantee allotment?

No, higher Symbiotec Pharmalab IPO subscription does not guarantee . In case of oversubscription, is done through a lottery system as per SEBI guidelines.

Is Symbiotec Pharmalab IPO subscription data official?

Yes, the subscription data shown for Symbiotec Pharmalab IPO is based on official data released by stock exchanges, but it may change during the day.

How does Symbiotec Pharmalab IPO subscription impact listing?

IPO subscription indicates demand, but the actual listing performance depends on market conditions, company fundamentals, and investor sentiment at the time of listing.